- ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
- ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
- Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
- ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
- ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
- ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
- ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
More ▼
Key statistics
On Monday, Immunitybio Inc (IBRX:NSQ) closed at 5.71, 356.80% above the 52 week low of 1.25 set on Oct 19, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.85 |
---|---|
High | 5.89 |
Low | 5.60 |
Bid | 5.66 |
Offer | 5.73 |
Previous close | 5.71 |
Average volume | 1.92m |
---|---|
Shares outstanding | 691.57m |
Free float | 153.59m |
P/E (TTM) | -- |
Market cap | 4.24bn USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 21:00 BST.
More ▼